Ranibizumab

Phase 3

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

12mo

ROCHE⭐Phase 3

Ranibizumab Phase 3 Results Expected

Ranibizumab• Neovascular Age-related Macular Degeneration (nAMD)451

Jan 7

00%

Drug Information

Target Indication

Neovascular Age-related Macular Degeneration (nAMD)

Clinical Trial

Last updated: 1/2/2026

Developer

ROCHE

Roche Holding AG

Related Pipeline

Pain; Bone Neoplasms; Neoplasm Metastasis

Duchenne Muscular Dystrophy

Lymphocytic Leukemia, Chronic

Anemia

Hepatitis C, Chronic